drugset

drugset / Trial / NCT00243191

Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans

NCT00243191 ↗

Phase 2 Completed 18 enrolled Sarcoma Alliance for Research through Collaboration

Non-randomizedSingle-groupOpen-label

Summary

The purpose of this study is to examine the effect of imatinib on dermatofibrosarcoma protuberan tumors.

Timeline

Start: 2006-05
Primary completion: 2009-09
Completion: 2009-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Imatinib	Small molecule	400 mg	Oral

Indications